Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Pharma-Bio Serv, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
19.5
15.6
17.8
19.5
21.6
20.1
19.4
17
9.51
9
Cost of revenue
13.8
9.46
12.1
13.3
14.9
14.8
14.5
11.9
6.99
6.09
Gross profit
5.78
3.84
5.69
6.18
6.67
5.36
4.88
5.07
2.52
2.91
Selling, general and administrative
5.87
4.66
4.6
4.48
4.44
9.21
3.71
3.95
3.8
3.55
Operating income
-0.09
-0.78
-1.26
1.7
2.23
-3.85
1.17
1.12
-1.29
-0.64
Interest income
0
0.32
0.25
0.04
Other non-operating income
-0.06
0.04
0.44
0.53
0.06
1.98
0.01
0.57
0.53
0.54
Pre-tax income
-0.2
-0.77
1.52
2.22
2.29
-1.88
1.19
1.69
-0.76
-0.09
Income tax
0.05
0
2.79
0.14
0.24
0.21
0.18
0.38
0.02
0.01
Income from continuing operations
-0.82
1.09
1.7
1.17
1.12
-1.29
-0.64
Net income
-0.26
-1.41
1.28
2.09
2.05
-2.09
1.01
1.31
-0.78
-0.1
EBITDA
0.22
-0.67
-1.19
1.8
2.31
-3.78
1.23
1.17
-1.26
-0.58
EPS, basic
-0.01
-0.06
0.09
0.09
EPS, diluted
-0.01
-0.06
0.09
0.09
0.06
-0.03
-0.00
Shares, basic (weighted)
23
23.1
23.1
23.1
23
23
23
23
23
22.9
Shares, diluted (weighted)
23.2
23.1
23.1
23.1
23
23.2
23
23
23
23
Dividend per share
0.08
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
13.8
11.6
16
15.5
17.1
17.5
14.5
10.4
6.77
3.38
Short-term investments
0.02
0.03
0.04
0
0
4.53
5.98
7.48
Receivables
6.85
6.32
5.19
8.78
9.73
4.61
4.98
3.94
2.51
2.36
Other current assets
0.98
0.44
0.39
0.45
0.47
0.44
0.17
Total current assets
21.6
21.7
23.4
26
28.6
22.8
19.9
19.4
15.7
13.4
Property, plant and equipment
2.33
0.25
0.3
0.29
0.22
0.11
0.07
0.03
0.17
0.12
Lease right-of-use assets
0
0.85
0.64
0.5
0.36
0.2
0.03
Other non-current assets
0.04
0.42
0.42
0.37
0.27
0.35
0.13
0.11
0.23
0.12
Total assets
24
22.4
25.4
26.6
29.9
23.9
20.7
19.9
16.3
13.7
Accounts payable
2.09
1.42
2.14
1.59
1.95
2.07
1.63
1.47
1.13
0.99
Total current liabilities
2.16
1.54
2.57
3.67
3.79
2.67
2.11
2.15
1.89
1.74
Lease liabilities
0
0.63
0.49
0.35
0.19
0.03
0
Other non-current liabilities
0
0.02
0.02
Total liabilities
2.19
1.6
5.11
6.03
7.2
5.01
4.09
3.78
2.58
1.74
Paid-in capital
1.23
1.3
1.35
1.38
1.42
1.48
1.55
1.6
1.64
1.68
Retained earnings
21
19.6
19.1
19.5
21.5
17.7
15.3
14.9
12.4
10.5
Treasury stock
-0.23
-0.25
-0.3
-0.39
-0.39
-0.42
-0.5
-0.54
-0.55
-0.58
Other comprehensive income
-0.17
0.14
0.11
0.14
0.16
0.14
0.24
0.21
0.26
0.28
Shareholders' equity
21.8
20.7
20.3
20.6
22.7
18.9
16.6
16.1
13.7
11.9
Total equity
21.8
20.7
20.3
20.6
22.7
18.9
16.6
16.1
13.7
11.9
Total liabilities and equity
24
22.4
25.4
26.6
29.9
23.9
20.7
19.9
16.3
13.7
Shares outstanding
23
23.1
23.1
23
23
23
22.9
23
23
22.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-0.26
-1.41
1.28
2.09
2.05
-2.09
1.01
-1.31
0.78
-0.1
Depreciation and amortization
0.31
0.11
0.07
0.1
0.09
0.07
0.05
0.05
0.02
0.06
Stock-based compensation
0.09
0.06
0.05
0.03
0.04
0.06
0.07
0.05
0.05
0.04
Change in receivables
0.65
0.14
1.16
-3.59
0.94
-0.13
0.46
1.09
1.46
0.2
Cash from operations
0.71
-0.92
3.72
-2.21
1.51
0.8
0.59
1.89
-0.57
-0.21
Capital expenditures
-1.81
-0.06
-0.12
-0.06
-0.06
-0.01
-0.02
-0.01
-0.16
-0.01
Purchases of investments
0
-4.21
Sales and maturities of investments
0
0.04
0
Cash from investing
-1.78
-0.01
-0.12
1.84
-0.03
1.3
-0.02
-4.22
-1.36
-1.47
Share buybacks
-0.05
-0.02
-0.06
-0.09
-0
-0.03
-0.08
-0.03
-0.01
-0.03
Dividends paid
0
-1.73
-1.73
-3.45
-1.72
-1.72
-1.72
Cash from financing
-0.07
-0.07
-1.8
-0.16
0.2
-1.75
-3.53
-1.76
-1.73
-1.75
Exchange rate effect
0.02
0
-0.09
-0.01
-0.04
-0.02
-0.05
0.07
-0.02
0.04
Net change in cash
-1.12
-2.18
4.44
-0.54
1.65
0.33
-3.01
-4.02
-3.68
-3.39
Free cash flow
-1.1
-0.98
3.6
-2.27
1.46
0.79
0.57
1.88
-0.73
-0.22
Interest paid
0
0
0
0
0
0
0
0
0
0
Income taxes paid
0.04
0
0
0.33
0.21
0.57
0.21
0.42
0.66
0.53
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.35 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
32.3%
Gross profit / revenue.
Operating margin
-1.6%
Operating income / revenue.
EBITDA margin
-1.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
2.8%
Pre-tax income / revenue.
Net margin
2.7%
Net income / revenue.
FCF margin
-4.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-4.4%
Cash from operations / revenue.
Effective tax rate
6.5%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
2.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
2.2%
Net income / average total assets.
Return on invested capital (ROIC)
-1.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
SG&A / revenue
34.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
0.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
0.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-5.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-22.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-16.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
15.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-15.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-15.3%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-13.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-10.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-12.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-16.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-14.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
-0.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-0.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-0.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.3x
Current assets / current liabilities.
Quick ratio
11.1x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.62x
(Cash + short-term investments) / current liabilities.
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.01
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.41
Revenue / diluted weighted shares.
FCF per share
-$0.02
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.02
Cash from operations / diluted weighted shares.
Book value per share
$0.46
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
31.9x
Market cap / net income. Only when net income is positive.
P/S
0.85x
Market cap / revenue.
P/B
0.77x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.77x
Market cap / tangible book value, when positive.
FCF yield
-5.3%
Free cash flow / market cap.
Earnings yield
3.1%
Net income / market cap (the inverse of P/E).
Shareholder yield
0.1%
(Dividends paid + share buybacks) / market cap.
What was Pharma-Bio Serv, Inc.'s revenue in fiscal 2025?
Pharma-Bio Serv, Inc. reported revenue of $9.0M for fiscal 2025, 5.3% lower than the year before.
Was Pharma-Bio Serv, Inc. profitable in fiscal 2025?
No. It reported a net loss of $100.5K.
How much free cash flow did Pharma-Bio Serv, Inc. generate in fiscal 2025?
Cash from operations of $214.9K minus capital expenditures of $6.6K left free cash flow of -$221.5K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.